What question did this study set out to answer?

This research aims to analyze the effectiveness of upadacitinib compared to other JAK inhibitors in achieving remission in rheumatoid arthritis patients.

April 17, 2026Open Access

Comparative Effectiveness of Upadacitinib vs. Other JAK Inhibitors in Patients With Rheumatoid Arthritis in a Global Real-World Setting

Key Points

This research aims to analyze the effectiveness of upadacitinib compared to other JAK inhibitors in achieving remission in rheumatoid arthritis patients.
Conducted as a real-world study
Compared outcomes among patients using upadacitinib and those using other JAK inhibitors
Assessed physician-reported DAS28 remission and medication adherence
Patients receiving upadacitinib achieved higher DAS28 remission rates
Greater absence of pain reported in patients on upadacitinib
Patients on upadacitinib showed complete adherence to medication more than those on other JAK inhibitors

Abstract

This real-world study of patients with RA showed that greater proportions of patients who received upadacitinib attained physician-reported DAS28 remission, absence of pain, and complete adherence to medication compared with patients receiving other JAKis.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper